Core Insights - Leronlimab treatment is associated with the upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells, leading to remarkably longer survival in patients when combined with immune checkpoint inhibitors [1][4] - A poster presentation at the San Antonio Breast Cancer Symposium highlights the sustained clinical benefits of leronlimab, with 17.9% of participants remaining alive and disease-free after treatment [2][4] Summary by Sections Clinical Findings - In a pooled analysis, 5 out of 28 women with metastatic triple-negative breast cancer (mTNBC) treated with leronlimab were alive and disease-free after five years, indicating sustained clinical benefit [2] - The median overall survival after starting leronlimab was 7.1 months, with survival rates at years 1, 2, 3, and 4 being 35.7%, 21.4%, 17.9%, and 17.9% respectively [4] - Patients receiving higher doses of leronlimab (525 mg or 700 mg) demonstrated significantly longer survival compared to those treated with a 350 mg dose [4] Mechanistic Insights - Leronlimab's ability to upregulate PD-L1 on circulating tumor cells (CTCs) could enhance the efficacy of combined treatment approaches with immune checkpoint inhibitors [4] - In 76% of patients overall, and 88% of those receiving higher doses, PD-L1 upregulation was observed in CTCs and cancer-associated macrophage-like cells [4] Treatment Tolerability - Weekly injections of leronlimab were well tolerated, with no dose-limiting toxicities reported and no patients withdrawing due to treatment-related adverse events [2][4] Future Directions - The company emphasizes the need for prospective confirmation of these observations to further explore the potential of leronlimab in oncology [5]